Navigation Links
RNA splicing factor implicated in ovarian tumor cell growth

An RNA-binding protein that is overproduced in ovarian cancer may present a new target for diagnosis or treatment of ovarian and other cancers, according to researchers at the University of Illinois at Chicago.

Researchers in the UIC College of Pharmacy found that interfering with the production of a splicing factor can inhibit the growth and invasiveness of tumor cells in test-tube experiments.

"In a previous study, we observed that human ovarian tumors overexpressed polypyrimidine tract-binding protein, or PTB, and another splicing factor compared to normal matching ovarian tissues," said William Beck, professor and head of biopharmaceutical sciences.

In the new study, Beck and research assistant professor Xiaolong He show that knocking down PTB expression with small, interfering RNA "substantially impairs ovarian tumor cell growth, colony formation and invasiveness."

The research has been published in the online version of the journal Oncogene; it will appear in an upcoming issue of the journal's print version.

Ovarian cancer is commonly referred to as "the silent killer," as it usually is not discovered until its advanced stages. If diagnosed and treated while the cancer is confined to the ovary, the 5-year survival rate is more than 90 percent, according to the American Cancer Society. Unfortunately, only 19 percent of all cases are found in the early stages.

One woman in 58 will develop ovarian cancer during her lifetime, the American Cancer Society said. In 2006, it was estimated that there were 20,180 new cases of ovarian cancer; 15,310 women were expected to die from the disease.

"Ovarian cancer is the deadliest disease among all gynecological cancers," said He. "Two factors account for the dismal mortality outcomes. One is the absence of reliable early detection markers, and the other is inadequacy of present therapy for advanced disease. To improve patient survival, it is critical to iden tify new biomarkers for early detection."

Polypyrimidine tract-binding protein is a key regulator of splicing, Beck said. Defects in pre-messenger RNA splicing have been shown to cause a variety of human diseases. Evidence suggests that altered splicing is associated with and possibly involved in tumor progression or metastasis.

"To the best of our knowledge, this is the first time anyone has shown that interference with the production of a splicing factor can inhibit tumor cell growth and tumor invasiveness," Beck said. "Alternatively-spliced genes and splicing factors are likely to play a key role as therapeutic targets and diagnostic markers in the next decade."


Source:University of Illinois at Chicago

Related biology news :

1. RNA splicing occurs in nerve-cell dendrites
2. Protein splicing upsets the DNA colinearity paradigm
3. RNA map provides first comprehensive understanding of alternative splicing
4. Cracking the olfactory code in bees
5. The first impact factor for PLoS Biology ?13.9
6. Open Access journals get impressive impact factors
7. Novel plague virulence factor identified
8. Microreactor efficiently regenerates cofactors for biocatalysis
9. Making plant cells work like miniature factories
10. Studies clarify risk factors for mother-to-child transmission of hepatitis C virus
11. DNA size a crucial factor in genetic mutations, study finds
Post Your Comments:

(Date:10/8/2015)... SAN JOSE, Calif. , Oct. 8, 2015 ... leading developer of human interface solutions, announced today ... first quarter of fiscal 2016 on Thursday, October ... company will host a corresponding conference call for ... p.m. ET), during which management may discuss forward-looking ...
(Date:10/8/2015)... NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that revenues for the three months ended ... $113,00 for the three months ended June 30, ... 30, 2015 were approximately $520,000.      ...
(Date:10/7/2015)... Connecticut , October 7, 2015 ... authentication company focused on the growing mobile commerce market ... Stanley E. Washington , former long- term executive ... of Directors. --> NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... cell surface marker detection market ... to a new report by Grand View Research, Inc. This ... of oncology diseases and other cell-associated disorders. --> ... USD 6.49 billion by 2022, according to a new report ... be attributed to rise in incidence of oncology diseases and ...
(Date:10/12/2015)...  Patara Pharma, a clinical-stage biotechnology company developing ... conditions, today announced the closing of a $26 ... the close of its sale of preferred stock, ... Agreement with Silicon Valley Bank whereby the Company ... use the funds from the financing to evaluate ...
(Date:10/12/2015)... , Belgium , Oct. 12, 2015 /PRNewswire/ ... that full results from a completed clinical study of its ... have been published in the online issue of Clinical ... The peer-reviewed study was conducted in collaboration with ... led by Roland Andersson , MD, PhD, Professor of ...
(Date:10/12/2015)... ... ... LifeTrak , a leader in consumer fitness, heart rate and activity ... tracker that seeks to meet the needs of multi-sport athletes. Zoom is the first ... both in water and on land, making it the only fitness tracker an athlete ...
Breaking Biology Technology: